Moderna is creating first in class in vivo medicines known as messenger RNA Therapeutics™, which enable the body to produce its own healing proteins. This is a quantum change in the way protein therapeutics are produced and used, creating the possibility to treat unmet medical needs that cannot be addressed with current technologies.
Our novel chemistry enables messenger RNA to elude the body’s innate immune response. Once delivered, stable messenger RNA is translated into active, native protein by cells’ natural, well-tuned machinery for protein production. Messenger RNA Therapeutics™ enable the in vivo production of both intracellular proteins, which remain within the cells, and secreted proteins, which are released into the bloodstream and act to restore function elsewhere in the body.
Messenger RNA has unique advantages as a platform, as novel drugs may be made and dosed in biolocally relevant ways with unprecedented ease and speed:
To date, we have made great strides in advancing messenger RNA as a drug platform, and have screened more than 100 new chemistries. Our current formulation represents a 50-fold increase in in vivo protein expression over our first generation chemistry, even as we have exponentially reduced the cost associated with manufacturing our messenger RNA Therapeutics™.